Real Hope For Cancer Patients | Precision Biologics

UNIQUE DISCOVERY PLATFORM

realize our potential

LEARN MORE

We have a platform of patient tumor
derived anticancer vaccines.

THERAPEUTICS

leaders in biotherapeutics

LEARN MORE

Our unique platform, combined with breakthroughs in biotechnology, enable us to produce targeted antibodies that weren’t possible just a few years ago.

COMPANION DIAGNOSTICS

explore our program

LEARN MORE

Our monoclonal antibodies are designed to target the tumor without harming healthy cells.

Precision Biologics is dedicated to improving the lives of cancer patients through its innovative therapeutic and diagnostic products.

Precision Biologics’ Collaborators at NHLBI/NIH and U Va to Reveal New AML Target for CAR-NK at American Association for Cancer Research (AACR) Annual Meeting on April 19th, 2026, San Diego, CA

DATE: April 17, 2026

Precision Biologics, Inc. CEO to present at the online Antibody-Drug Conjugates MicroSummit conference, March 17th, 2026.

DATE: March 12, 2026

Precision Biologics featured in Pharma Device News article March 8, 2026

DATE: March 8, 2026

Precision Biologics, Inc. CEO Philip M. Arlen, MD, to give presentation on monoclonal antibodies against tumor-specific targets at Festival of Biologics USA, San Diego Convention Center, San Diego, CA, March 4-5, 2026

DATE: March 2, 2026

Dr. Philip M Arlen to present Keynote at the 6th Ace Drug Discovery Summit, London, UK, February 19, 2026

DATE: February 17, 2026

Precision Biologics to Reveal Preclinical Efficacy of Novel Tumor-Specific ADC against multiple human cancer types at SITC 2025

DATE: November 5, 2025

# of people living with cancer in the US

annual # of new cases of cancer in the US

annual # of deaths from cancer in the US

*Source: seer.cancer.gov/statfacts (2024)